{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:13:07Z","timestamp":1792815187992,"version":"4.5.0"},"reference-count":104,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Primary mediastinal large B-cell lymphoma (PMBCL) is a separate entity in the World Health Organization\u2019s classification, based on clinicopathologic features and a distinct molecular signature that overlaps with nodular sclerosis classic Hodgkin lymphoma (cHL). Molecular classifiers can distinguish PMBCL from diffuse large B-cell lymphoma (DLBCL) using ribonucleic acid derived from paraffin-embedded tissue and are integral to future studies. However, given that \u223c5% of DLBCL can have a molecular PMBCL phenotype in the absence of mediastinal involvement, clinical information remains critical for diagnosis. Studies during the past 10 to 20 years have elucidated the biologic hallmarks of PMBCL that are reminiscent of cHL, including the importance of the JAK-STAT and NF-\u03baB signaling pathways, as well as an immune evasion phenotype through multiple converging genetic aberrations. The outcome of PMBCL has improved in the modern rituximab era; however, whether there is a single standard treatment for all patients and when to integrate radiotherapy remains controversial. Regardless of the frontline therapy, refractory disease can occur in up to 10% of patients and correlates with poor outcome. With emerging data supporting the high efficacy of PD1 inhibitors in PMBCL, studies are underway that integrate them into the up-front setting.<\/jats:p>","DOI":"10.1182\/blood.2020008376","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T20:58:38Z","timestamp":1631134718000},"page":"955-970","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":66,"title":["Primary mediastinal large B-cell lymphoma"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9863","authenticated-orcid":false,"given":"Kerry J.","family":"Savage","sequence":"first","affiliation":[{"name":"Centre for Lymphoid Cancer and"},{"name":"Division of Medical Oncology, University of British Columbia, BC Cancer, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2022090115232752700_B1","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood."},{"issue":"6","key":"2022090115232752700_B2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med."},{"key":"2022090115232752700_B3","volume-title":"WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues.","author":"Gaulard","year":"2008","edition":"4th ed"},{"issue":"3","key":"2022090115232752700_B4","first-page":"549","article-title":"Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+\u00a0Hodgkin cells","volume":"60","author":"Joos","year":"2000","journal-title":"Cancer Res."},{"issue":"4","key":"2022090115232752700_B5","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1182\/blood.V87.4.1571.bloodjournal8741571","article-title":"Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene","volume":"87","author":"Joos","year":"1996","journal-title":"Blood."},{"issue":"4","key":"2022090115232752700_B6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/1098-2264(2001)9999:9999<::AID-GCC1105>3.0.CO;2-I","article-title":"Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line","volume":"30","author":"Bentz","year":"2001","journal-title":"Genes Chromosomes Cancer."},{"issue":"8","key":"2022090115232752700_B7","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.3109\/10428194.2014.985673","article-title":"Structural genomic alterations in primary mediastinal large B-cell lymphoma","volume":"56","author":"Twa","year":"2015","journal-title":"Leuk Lymphoma."},{"issue":"7338","key":"2022090115232752700_B8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature."},{"issue":"1","key":"2022090115232752700_B9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2005-11-4742","article-title":"Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival","volume":"108","author":"Roberts","year":"2006","journal-title":"Blood."},{"issue":"12","key":"2022090115232752700_B10","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/PAS.0000000000000297","article-title":"Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain","volume":"38","author":"Shi","year":"2014","journal-title":"Am J Surg Pathol."},{"issue":"5","key":"2022090115232752700_B11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/ejh.13033","article-title":"Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma","volume":"100","author":"Tanaka","year":"2018","journal-title":"Eur J Haematol."},{"key":"2022090115232752700_B12","first-page":"314","volume-title":"WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues.","author":"Gaulard","year":"2017","edition":"Revised 4th ed"},{"issue":"24","key":"2022090115232752700_B13","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1182\/blood.2019004296","article-title":"Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET-adapted approach","volume":"136","author":"Hayden","year":"2020","journal-title":"Blood."},{"issue":"5","key":"2022090115232752700_B14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.14951","article-title":"Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R","volume":"179","author":"Giulino-Roth","year":"2017","journal-title":"Br J Haematol."},{"issue":"12","key":"2022090115232752700_B15","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3324\/haematol.2014.111203","article-title":"Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan","volume":"99","author":"Aoki","year":"2014","journal-title":"Haematologica."},{"issue":"12","key":"2022090115232752700_B16","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/modpathol.2012.129","article-title":"Utility of CD200 immunostaining in the diagnosis of primary mediastinal large B cell lymphoma: comparison with MAL, CD23, and other markers","volume":"25","author":"Dorfman","year":"2012","journal-title":"Mod Pathol."},{"issue":"23","key":"2022090115232752700_B17","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2022090115232752700_B18","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1182\/blood-2005-06-2502","article-title":"AID expression identifies interfollicular large B cells as putative precursors of mature B-cell malignancies","volume":"107","author":"Moldenhauer","year":"2006","journal-title":"Blood."},{"issue":"2","key":"2022090115232752700_B19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/PAS.0000000000000771","article-title":"Performance of a commercially available MAL antibody in the diagnosis of primary mediastinal large B-cell lymphoma","volume":"41","author":"Gentry","year":"2017","journal-title":"Am J Surg Pathol."},{"issue":"13","key":"2022090115232752700_B20","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"13","key":"2022090115232752700_B21","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.2020007507","article-title":"Mutational landscape of gray zone lymphoma","volume":"137","author":"Sarkozy","year":"2021","journal-title":"Blood."},{"issue":"2","key":"2022090115232752700_B22","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/2643-3230.BCD-20-0009","article-title":"Gene expression profiling of mediastinal gray zone lymphoma and its relationship to primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma","volume":"1","author":"Pittaluga","year":"2020","journal-title":"Blood Cancer Discov."},{"issue":"11","key":"2022090115232752700_B23","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1182\/bloodadvances.2020001923","article-title":"Gene expression profiling of gray zone lymphoma","volume":"4","author":"Sarkozy","year":"2020","journal-title":"Blood Adv."},{"issue":"26","key":"2022090115232752700_B24","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies","volume":"33","author":"Scott","year":"2015","journal-title":"J Clin Oncol."},{"issue":"22","key":"2022090115232752700_B25","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2018-05-851154","article-title":"Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens","volume":"132","author":"Mottok","year":"2018","journal-title":"Blood."},{"issue":"3","key":"2022090115232752700_B26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022090115232752700_B27","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jmoldx.2017.07.007","article-title":"Determination of molecular subtypes of diffuse large B-cell lymphoma using a reverse transcriptase multiplex ligation-dependent probe amplification classifier: a CALYM study","volume":"19","author":"Bob\u00e9e","year":"2017","journal-title":"J Mol Diagn."},{"issue":"5","key":"2022090115232752700_B28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma","volume":"206","author":"Schmitz","year":"2009","journal-title":"J Exp Med."},{"issue":"23","key":"2022090115232752700_B29","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1182\/blood-2016-03-704528","article-title":"Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma","volume":"128","author":"Mansouri","year":"2016","journal-title":"Blood."},{"issue":"18","key":"2022090115232752700_B30","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood-2017-09-808907","article-title":"Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation","volume":"131","author":"Vigan\u00f2","year":"2018","journal-title":"Blood."},{"issue":"17","key":"2022090115232752700_B31","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood."},{"issue":"4","key":"2022090115232752700_B32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ng.2900","article-title":"Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma","volume":"46","author":"Gunawardana","year":"2014","journal-title":"Nat Genet."},{"issue":"6","key":"2022090115232752700_B33","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2009-03-209759","article-title":"Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma","volume":"114","author":"Ritz","year":"2009","journal-title":"Blood."},{"issue":"10","key":"2022090115232752700_B34","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.2019001126","article-title":"Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma","volume":"134","author":"Mottok","year":"2019","journal-title":"Blood."},{"issue":"26","key":"2022090115232752700_B35","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/blood.2019002067","article-title":"Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade","volume":"134","author":"Chapuy","year":"2019","journal-title":"Blood."},{"issue":"9","key":"2022090115232752700_B36","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood-2015-11-683003","article-title":"Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas","volume":"128","author":"Chong","year":"2016","journal-title":"Blood."},{"issue":"13","key":"2022090115232752700_B37","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood."},{"issue":"4","key":"2022090115232752700_B38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MOH.0000000000000155","article-title":"Genomic alterations underlying immune privilege in malignant lymphomas","volume":"22","author":"Mottok","year":"2015","journal-title":"Curr Opin Hematol."},{"issue":"10","key":"2022090115232752700_B39","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/gcc.22276","article-title":"Alterations of the CD58 gene in classical Hodgkin lymphoma","volume":"54","author":"Schneider","year":"2015","journal-title":"Genes Chromosomes Cancer."},{"issue":"6","key":"2022090115232752700_B40","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of \u03b22-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell."},{"issue":"10","key":"2022090115232752700_B41","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1097\/PAS.0000000000000473","article-title":"Identification of primary mediastinal large B-cell lymphoma at nonmediastinal sites by gene expression profiling","volume":"39","author":"Yuan","year":"2015","journal-title":"Am J Surg Pathol."},{"issue":"2","key":"2022090115232752700_B42","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood.2020007683","article-title":"Characterization of DLBCL with a PMBL gene expression signature","volume":"138","author":"Duns","year":"2021","journal-title":"Blood."},{"issue":"5","key":"2022090115232752700_B43","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published correction appears in Nat Med. 2018;24(8):129 and Nat Med. 2018;24(8):1290]","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med."},{"issue":"15","key":"2022090115232752700_B44","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med."},{"issue":"4","key":"2022090115232752700_B45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell."},{"issue":"20","key":"2022090115232752700_B46","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood."},{"issue":"1","key":"2022090115232752700_B47","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12885-017-3332-3","article-title":"Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma","volume":"17","author":"Lisenko","year":"2017","journal-title":"BMC Cancer."},{"issue":"2","key":"2022090115232752700_B48","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1634\/theoncologist.2011-0275","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care","volume":"17","author":"Vassilakopoulos","year":"2012","journal-title":"Oncologist."},{"issue":"3","key":"2022090115232752700_B49","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/annonc\/mdq418","article-title":"Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study","volume":"22","author":"Rieger","year":"2011","journal-title":"Ann Oncol."},{"issue":"8","key":"2022090115232752700_B50","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3109\/10428194.2012.746684","article-title":"Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy","volume":"54","author":"Xu","year":"2013","journal-title":"Leuk Lymphoma."},{"issue":"5","key":"2022090115232752700_B51","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3816\/CLM.2009.n.074","article-title":"Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study","volume":"9","author":"Zinzani","year":"2009","journal-title":"Clin Lymphoma Myeloma."},{"issue":"8","key":"2022090115232752700_B52","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00277-014-2043-y","article-title":"The impact of R-VACOP-B and interim FDG-PET\/CT on outcome in primary mediastinal large B cell lymphoma","volume":"93","author":"Avigdor","year":"2014","journal-title":"Ann Hematol."},{"issue":"8","key":"2022090115232752700_B53","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson","year":"2002","journal-title":"Blood."},{"issue":"15","key":"2022090115232752700_B54","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med."},{"issue":"2","key":"2022090115232752700_B55","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/1097-0142(19810115)47:2<300::AID-CNCR2820470216>3.0.CO;2-7","article-title":"Cutaneous malignant lymphoma: a pathologic study of 50 cases with clinical analysis of 37","volume":"47","author":"Burke","year":"1981","journal-title":"Cancer."},{"issue":"21","key":"2022090115232752700_B56","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the Phase III Intergroup Trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022090115232752700_B57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41408-020-0312-7","article-title":"Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up","volume":"10","author":"Zhou","year":"2020","journal-title":"Blood Cancer J."},{"issue":"4","key":"2022090115232752700_B58","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.15051","article-title":"R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis","volume":"180","author":"Shah","year":"2018","journal-title":"Br J Haematol."},{"issue":"1","key":"2022090115232752700_B59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ejh.13337","article-title":"Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma","volume":"104","author":"Malenda","year":"2020","journal-title":"Eur J Haematol."},{"issue":"12","key":"2022090115232752700_B60","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.clml.2018.08.014","article-title":"Complications associated with dose-adjusted EPOCH-rituximab therapy for non-Hodgkin lymphoma","volume":"18","author":"David","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"issue":"1","key":"2022090115232752700_B61","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijrobp.2015.09.017","article-title":"Improved survival with radiation therapy in stage I-II primary mediastinal B cell lymphoma: a surveillance, epidemiology, and end results database analysis","volume":"94","author":"Jackson","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"11","key":"2022090115232752700_B62","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/ajh.24172","article-title":"Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: a US population-based analysis","volume":"90","author":"Giri","year":"2015","journal-title":"Am J Hematol."},{"issue":"1","key":"2022090115232752700_B63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijrobp.2016.10.004","article-title":"Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma","volume":"97","author":"Conway","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"9","key":"2022090115232752700_B64","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1470-2045(16)30215-7","article-title":"Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin\u2019s lymphoma: an analysis from the St Jude Lifetime Cohort Study","volume":"17","author":"Bhakta","year":"2016","journal-title":"Lancet Oncol."},{"issue":"26","key":"2022090115232752700_B65","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med."},{"issue":"4","key":"2022090115232752700_B66","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hon.2172","article-title":"The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients","volume":"33","author":"Zinzani","year":"2015","journal-title":"Hematol Oncol."},{"issue":"27","key":"2022090115232752700_B67","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol."},{"issue":"17","key":"2022090115232752700_B68","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2013.51.7524","article-title":"[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study [published correction appears in J Clin Oncol. 2016;34(21):2562]","volume":"32","author":"Martelli","year":"2014","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022090115232752700_B69","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/leu.2015.120","article-title":"PET\/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy","volume":"30","author":"Vassilakopoulos","year":"2016","journal-title":"Leukemia."},{"issue":"9","key":"2022090115232752700_B70","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00277-021-04421-2","article-title":"Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies","volume":"100","author":"Vassilakopoulos","year":"2021","journal-title":"Ann Hematol."},{"issue":"11","key":"2022090115232752700_B71","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/bloodadvances.2018017681","article-title":"Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL","volume":"2","author":"Pinnix","year":"2018","journal-title":"Blood Adv."},{"issue":"8","key":"2022090115232752700_B72","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3324\/haematol.2018.192492","article-title":"End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making","volume":"103","author":"Melani","year":"2018","journal-title":"Haematologica."},{"issue":"8","key":"2022090115232752700_B73","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1038\/leu.2016.109","article-title":"Response to \u2018PET after response to R-CHOP in primary mediastinal large B-cell lymphoma\u2019","volume":"30","author":"Vassilakopoulos","year":"2016","journal-title":"Leukemia."},{"issue":"1","key":"2022090115232752700_B74","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2016.09.031","article-title":"Positron emission tomography\/computed tomography assessment after immunochemotherapy and irradiation using the Lugano classification criteria in the IELSG-26 study of primary mediastinal B-cell lymphoma","volume":"97","author":"Ceriani","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"2","key":"2022090115232752700_B75","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood-2018-01-826958","article-title":"Metabolic heterogeneity on baseline 18FDG-PET\/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma","volume":"132","author":"Ceriani","year":"2018","journal-title":"Blood."},{"issue":"10","key":"2022090115232752700_B76","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.bbmt.2018.06.009","article-title":"Outcomes of relapsed and refractory primary mediastinal (Thymic) large B cell lymphoma treated with second-line therapy and intent to transplant","volume":"24","author":"Vardhana","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"issue":"12","key":"2022090115232752700_B77","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1038\/bcj.2015.101","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"5","author":"Aoki","year":"2015","journal-title":"Blood Cancer J."},{"issue":"8","key":"2022090115232752700_B78","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41409-017-0063-7","article-title":"Autologous stem cell transplantation for primary mediastinal B-cell lymphoma: long-term outcome and role of post-transplant radiotherapy. A report of the European Society for Blood and Marrow Transplantation","volume":"53","author":"Avivi","year":"2018","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"2022090115232752700_B79","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood."},{"issue":"34","key":"2022090115232752700_B80","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol."},{"issue":"33","key":"2022090115232752700_B81","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the Phase II CheckMate 436 Study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J Clin Oncol."},{"issue":"16","key":"2022090115232752700_B82","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2017-01-764258","article-title":"Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial","volume":"129","author":"Zinzani","year":"2017","journal-title":"Blood."},{"issue":"16","key":"2022090115232752700_B83","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood. 2018;131(5):587-588]","volume":"130","author":"Crump","year":"2017","journal-title":"Blood."},{"issue":"26","key":"2022090115232752700_B84","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"2022090115232752700_B85","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"10254","key":"2022090115232752700_B86","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet."},{"issue":"6","key":"2022090115232752700_B87","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3324\/haematol.2019.238675","article-title":"Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas","volume":"106","author":"Svoboda","year":"2021","journal-title":"Haematologica."},{"issue":"1","key":"2022090115232752700_B88","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1186\/s12885-019-6303-z","article-title":"Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Cancer."},{"issue":"5","key":"2022090115232752700_B89","first-page":"905","article-title":"Combined PD-1 and JAK1\/2 inhibition in refractory primary mediastinal B-cell lymphoma","volume":"97","author":"Nijland","year":"2018","journal-title":"Ann Hematol."},{"issue":"12","key":"2022090115232752700_B90","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/modpathol.2011.116","article-title":"Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations","volume":"24","author":"Eberle","year":"2011","journal-title":"Mod Pathol."},{"issue":"1","key":"2022090115232752700_B91","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3324\/haematol.2016.152256","article-title":"Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association","volume":"102","author":"Sarkozy","year":"2017","journal-title":"Haematologica."},{"key":"2022090115232752700_B92","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-131450","article-title":"Diffuse large B-cell lymphomas with a molecular PMBCL expression signature represent a distinct molecular subtype associated with poor clinical outcome [abstract]","volume":"134","author":"Duns","year":"2019","journal-title":"Blood."},{"issue":"21","key":"2022090115232752700_B93","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.420.420","article-title":"Sequential dose-dense RCHOP followed by ICE consolidation (MSKCC protocol 01\u2013142) without radiotherapy for patients with primary mediastinal large B cell lymphoma [abstract]","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood."},{"issue":"4","key":"2022090115232752700_B94","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bjh.14287","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial","volume":"175","author":"Gleeson","year":"2016","journal-title":"Br J Haematol."},{"issue":"33","key":"2022090115232752700_B95","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1200\/JCO.21.00920","article-title":"Dose-adjusted etoposide, doxorubicin, andcyclophosphamide with vincristine and prednisone plus rituximab therapy in children and adolescents with primary mediastinal B-cell lymphoma: a multicenter phase II trial","volume":"39","author":"Burke","year":"2021","journal-title":"J Clin Oncol"},{"key":"2022090115232752700_B96","article-title":"Role of radiotherapy and dose-densificaiton of R-CHOP in primary mediastinal large B-cell lymphoma: a subgroup analysis of the UNFOLDER trial of the German Lymphoma Alliance (GLA) [abstract]","author":"Held","year":"2020","journal-title":"EHA Library"},{"issue":"3","key":"2022090115232752700_B97","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12185-010-0536-6","article-title":"Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients","volume":"91","author":"Ahn","year":"2010","journal-title":"Int J Hematol."},{"issue":"3","key":"2022090115232752700_B98","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3109\/10428194.2013.810738","article-title":"Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease","volume":"55","author":"Soumerai","year":"2014","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2022090115232752700_B99","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ijrobp.2015.02.006","article-title":"Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography","volume":"92","author":"Pinnix","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5","key":"2022090115232752700_B100","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00280-016-3024-8","article-title":"Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy","volume":"77","author":"Goldschmidt","year":"2016","journal-title":"Cancer Chemother Pharmacol."},{"issue":"5","key":"2022090115232752700_B101","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/10428194.2018.1519812","article-title":"R-CHOP without radiation in frontline management of primary mediastinal B-cell lymphoma","volume":"60","author":"Messmer","year":"2019","journal-title":"Leuk Lymphoma."},{"issue":"10","key":"2022090115232752700_B102","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1002\/cam4.2347","article-title":"Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma","volume":"8","author":"Chan","year":"2019","journal-title":"Cancer Med."},{"issue":"5","key":"2022090115232752700_B103","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41408-021-00491-7","article-title":"Real-world data on treatment and outcomes of patients with primary mediastinal large B-cell lymphoma: a Swedish lymphoma register study","volume":"11","author":"W\u00e4sterlid","year":"2021","journal-title":"Blood Cancer J."},{"issue":"7","key":"2022090115232752700_B104","first-page":"1329","article-title":"Outcomes of salvage chemotherapy and autologous stem cell transplanatation for relapsed or refractory primary medistianal large B-cell lymphoma (PMLCL) are inferior to diffuse large B-cell lymphoma [abstract]","volume":"49","author":"Kuruvilla","year":"2008","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/9\/955\/1917715\/bloodbld2020008376c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/9\/955\/1917715\/bloodbld2020008376c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T15:26:01Z","timestamp":1662045961000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/9\/955\/476814\/Primary-mediastinal-large-B-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":104,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008376","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}